Crimson Publishers Publish With Us Reprints e-Books Video articles


Advancements in Bioequivalence & Bioavailability

SiRNA Delivery for Cancer Therapy: Challenges and Future Perspective

  • Open or Close Mohana Mukherjee1 and Suvadeep Sen2*

    1Department of Chemical Engineering, IIT Bombay, India

    2Critical care medicine, Apollo Hospital, India

    *Corresponding author: Suvadeep Sen, Junior consultant, Critical care medicine, Apollo Hospital, Navi Mumbai, Maharashtra, India

Submission: May 28, 2018; Published: July 18, 2018

DOI: 10.31031/ABB.2018.01.000518

ISSN 2640-9275
Volume1 Issue4


Cancer is one of the leading causes of death across the globe. Despite advancement of conventional treatments, the safety and efficacy of various chemotherapeutic drugs remained questionable. Recent advances in biotechnology and discovery of siRNA and RNA interference mechanism has brought a new light in more specific and targeted treatment of malignant tissue. Important advantage of siRNA-based therapy is its target specificity and safety, but disadvantage is to build an appropriate vehicle for its delivery into target site. Various phase I and II clinical trials are under way to test the efficacy of this new modality of treatment.

Keywords: SiRNA; RNA interference; Cancer therapy

Abbreviations: SiRNA: Small Interfering Ribonucleic Acid; WHO: World Health Organization; RNA: Ribonucleic Acid; DNA: Deoxyribonucleic Acid; RISC: RNA Induced Silencing Complex; Mrna: Messenger Ribonucleic Acid; VEGF: Vascular Endothelial Growth Factor; KSP: Kinesin Spindle Protein; PKN3: Protein Kinase N3; BCL-2: B-Cell Lymphoma 2; Kda: Kilo Dalton

Get access to the full text of this article